ArticleCost effectiveness and resource allocation : C/E2023

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore.

Jian Chun Matthew Ong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.